Sight Sciences, INC

Sight Sciences, Inc. announced the successful election of two directors and the ratification of its independent auditor at its 2026 annual meeting.

Sight Sciences secured a $55.4 million judgment in a patent infringement lawsuit against Alcon concerning Alcon's Hydrus Microstent.

A Delaware court preserved Sight Sciences’ willful infringement verdict against Alcon, awarding $34M plus interest and a 10% Hydrus royalty through November 2028.

Sight Sciences reported a return to growth in Q4 2025, driven by Interventional Glaucoma, and initiated positive revenue guidance for 2026.

Sight Sciences, Inc. announced a 26-month extension for its Menlo Park headquarters lease, including a two-month rent abatement period.

Sight Sciences announced preliminary unaudited financial highlights for Q4 and full year 2025, showing strong Q4 revenue growth but a full-year decline.

Sight Sciences, Inc. reported a narrower net loss in Q3 2025, driven by significant operating expense reductions and workforce restructuring, despite an overall revenue decline.

Sight Sciences reported a significant revenue decline in Q2 2025, driven by reduced Surgical Glaucoma sales due to Medicare reimbursement changes and decreased Dry Eye demand following a price increase.

Sight Sciences' Q1 2025 revenue decreased by 9.1% year-over-year, primarily due to challenges in the Surgical Glaucoma segment and lower demand for Dry Eye products following a price increase.

Sight Sciences reported its third quarter 2024 financial results, highlighting a slight increase in Surgical Glaucoma revenue and addressing the impact of new Medicare coverage policies.

Sight Sciences reported a decrease in revenue for the second quarter of 2024, alongside a strategic realignment focused on long-term growth and profitability.

Sight Sciences' first quarter 2024 results show a slight increase in overall revenue, primarily driven by growth in the Surgical Glaucoma segment, while the Dry Eye segment experienced a decline.

Sight Sciences reports a net loss of $38.4 million for 2025, with flat Interventional Glaucoma revenue and a significant decline in Interventional Dry Eye sales, alongside a 20% workforce reduction.

Sight Sciences' 2024 results reveal a mixed performance, with Surgical Glaucoma revenue growth offset by Dry Eye revenue decline amid reimbursement hurdles.

Sight Sciences' 10-K filing outlines the company's capital structure, regulatory environment, and risk factors, highlighting its reliance on key products and the competitive landscape.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 12,733 shares of common stock to cover tax liabilities related to vested restricted stock units.

Sight Sciences, Inc. reports that Chief Financial Officer James Rodberg sold 6,902 shares of common stock to cover tax liabilities related to vesting restricted stock units.

David Badawi, Chief Technology Officer and Director at Sight Sciences, Inc., sold 7,418 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Brenton Taylor, EVP of Operations & R&D at Sight Sciences, Inc., sold 2,829 shares of common stock to cover tax liabilities related to vesting RSUs.

Sight Sciences, Inc. reports that Chief Operating Officer Alison Bauerlein sold shares to cover tax liabilities related to vested restricted stock units.

Sight Sciences, Inc. reports that President and CEO Paul Badawi sold 28,684 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.

Sight Sciences, Inc. has filed a definitive proxy statement with the SEC.

Sight Sciences, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on the election of directors and the ratification of the company's independent registered public accounting firm.

Sight Sciences, Inc. has filed a definitive proxy statement with the SEC.

Sight Sciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Allegro Investment Fund, L.P. and its affiliates, including director Staffan Encrantz, have significantly increased their beneficial ownership in Sight Sciences, Inc. to 13.1% through recent open market purchases, signaling continued investment interest.

KCK Ltd. and Nael Karim Kassar have reported beneficial ownership of 1,438,094 shares of Sight Sciences, Inc. common stock, representing 2.7% of the class.

KCK Ltd. and Nael Karim Kassar have reported a 7.0% beneficial ownership stake in Sight Sciences, Inc., holding 3,706,914 common shares.

BlackRock, Inc. has reported a beneficial ownership of 5.01% of Sight Sciences, Inc.'s common stock as of December 31, 2025.

Long Focus Capital Management, LLC and John Helmers have filed an amended Schedule 13G, reporting a 6.0% beneficial ownership stake in Sight Sciences, Inc. as of March 31, 2025.

KCK Ltd. and Nael Karim Kassar have reported a shared beneficial ownership of 8.6% in Sight Sciences, Inc., totaling 4,374,975 common shares as of December 31, 2024.

Long Focus Capital Management and related entities report beneficial ownership of 5% of Sight Sciences' common stock as of January 16, 2025.